摘要
目的:研究伊马替尼(IM)抑制T细胞增殖后miR-155和miR-181a的表达水平以及阻断miR-155表达是否能够改善IM对T细胞的增殖抑制作用。方法:不同浓度IM联合miR-155抑制剂作用Jurkat T细胞24 h,采用CCK-8技术检测细胞存活率;采用核酸蛋白仪检测RNA样品的纯度和浓度;采用实时荧光定量聚合酶链反应(PCR)技术检测miR-155和miR-181a基因表达水平变化。结果:IM明显上调Jurkat T细胞miR-155基因表达水平,差异有统计学意义(P<0.0001);miR-155抑制剂能够拮抗或改善IM对Jurkat T细胞增殖抑制作用。结论:阻断miR-155表达能够拮抗IM对T细胞的抑制作用。
Objective This study aimed to explore the expression level of miR-155 and miR-181a after imatinib mesylate(IM)inhibited T cell proliferation and whether blocking the expression of miR-155 improved the inhibitory effect of IM on T cells.Methods Different concentrations of IM combined with miR-155 inhibitors were used to treat Jurkat T cells for 24 hours,and the cell survival rate was measured using CCK-8;Using nucleic acid protein analyzer to detect the purity and concentration of RNA samples;Real-time quantitative polymerase chain reaction(PCR)was used to detect changes in the expression levels of miR-155 and miR-181a genes.Results IM significantly upregulated the gene expression level of miR-155 in Jurkat cells(P<0.0001),and miR-155 inhibitors could antagonize or improve the inhibitory effect of IM on T cell proliferation.Conclusions Blocking miR-155 expression can antagonize the inhibitory effect of IM on T cells.
作者
陈小华
邱华云
杨江勇
曹越
刘毅
邓文强
Chen Xiaohua;Qiu Huayun;Yang Jiangyong;Cao Yue;Liu Yi;Deng Wenqiang(Department of Medical Technology,Medical School,Shaoguan University,Shaoguan,Guangdong 512000,China;Department of Nursing,Medical College of Shaoguan University,Shaoguan,Guangdong 512000,China)
出处
《医药前沿》
2023年第33期4-8,共5页
Journal of Frontiers of Medicine
基金
韶关学院科研项目基金资助(EKY201905)
2023年度韶关市社会发展科技协同创新体系建设项目(230330178036357)。
